ClinicalTrials.gg
RecruitingNCT07656259Updated Aug 10, 2026

COMPARE-VENT Feasibility Pilot Study

An interventional study of Volume Controlled Mode and Pressure Controlled Mode in Respiration Failure, Cardio Vascular Disease and Cardiogenic Pulmonary Oedema, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 349 studies in Respiratory Insufficiency with a site in United States — 44 open to participants now, 60 under way, 1 of them phase 3. Respiratory Insufficiency · United States.

Planned enrollment
88th of 253
75 · median 42
Started
2026
with 17 others
No phase
159 of 349
30 open now
Primary completion
2027-02
later than 30 of 59 live
Registered
345th of 349
by date

Among the 349 studies in Respiratory Insufficiency with a site in United States, this one is the 88th largest by planned enrollment of the 253 interventional ones that give a count, is one of 18 that started in 2026, is one of 159 with no phase, reaches primary completion later than 30 of the 59 other live ones, and was the 345th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

44 of the 349 studies in Respiratory Insufficiency with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Respiratory Insufficiency with a site in United States, or all of them as a file.
02

Study summary

Cardiac disease complicated by respiratory insufficiency comprises the most frequent indication for cardiac intensive care unit (CICU) admission, with nearly one-third patients requiring advanced respiratory support and over 20% patients requiring invasive mechanical ventilation (IMV). IMV among patients with impaired cardiovascular reserve is further compounded by the adverse impact of positive pressure ventilation (PPV) and systemic sedation on intracardiac hemodynamics, pulmonary vascular mechanics and consequently end-organ perfusion. Despite widespread use, evidence guiding optimal ventilatory practices and mode selection in cardiovascular intensive care unit patients remains limited. Pressure-controlled and volume-controlled ventilation may differ in their effects on patient-ventilator synchrony, sedation requirements, and hemodynamic impact, but comparative data among patients with critical cardiac disease remains inconclusive. This pilot study will evaluate the feasibility of implementing a pragmatic cluster-randomized crossover trial comparing ventilatory modes in a contemporary cardiovascular intensive care unit.

03

Conditions studied

  • Respiration Failure
  • Cardio Vascular Disease
  • Cardiogenic Pulmonary Oedema
  • Critical Illness
  • Mechanical Ventilation
  • Cardiogenic Shock
  • Cardiopulmonary

Keywords

  • Cardiovascular disease
  • Cardiac arrest
  • Cardiogenic shock
  • Respiratory failure
  • Cardiopulmonary interactions
  • Critical illness
  • Intensive care unit
  • Critical care therapies
  • Outcomes
  • Mechanical ventilation
  • Positive pressure ventilation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligible adults ≥ 18 years of age admitted to the cardiac ICU with need for invasive mechanical ventilation of expected duration >12 hours.

Pre-Specified Subgroups for exploratory outcomes:

  1. SCAI Stages C-E Cardiogenic Shock
  2. Mechanical circulatory support use, including intra-aortic balloon pumps and microaxial flow pumps, including Impella CP, RP Impella Flex, and Impella 5.5 devices
  3. Heart failure with reduced : LVEF \<40% or;
  4. Moderate to severe RV systolic dysfunction or;
  5. Moderate to severe Pulmonary hypertension, as defined by ACC/AHA/ESC guidelines

Exclusion criteria

Exclusion Criteria:

  1. Expected duration of intubation \<12 hours.
  2. Severe , bronchopleural fistulas, or severe ARDS (Berlin criteria P/F \<100, in the absence of pulmonary edema)
  3. Home ventilator or chronic tracheostomy.
  4. Pregnant, incarcerated, patients or those receiving extracorporeal membrane oxygenation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    Pressure Controlled Ventilation

    During invasive mechanical ventilation in the cardiac ICU, pressure-controlled ventilation will be used as the mode for continuous mandatory ventilation.

    Other: Pressure Controlled Mode

  • Active comparator
    Volume-Controlled Ventilation

    During invasive mechanical ventilation in the cardiac ICU, volume-controlled ventilation will be used as the mode for continuous mandatory ventilation.

    Other: Volume Controlled Mode

Interventions

  • OtherVolume Controlled Mode

    Volume-controlled mode for continuous mandatory ventilation with preset inspiratory flow and tidal volume.

  • OtherPressure Controlled Mode

    Pressure-controlled mode for continuous mandatory ventilation with preset inspiratory pressure above positive end-expiratory pressure.

06

What researchers measure

Primary outcomes

  1. Adherance to assigned study mode (Feasibility Outcome)

    Percentage of time spent on the assigned study mode while receiving invasive mechanical ventilation in the cardiac ICU between enrollment and 48 hours after enrollment.

    Time frame: Enrollment to 48 hours

  2. Time From Enrollment to Initiation of Assigned Mode of Mechanical Ventilation (Feasibility Outcome)

    Time (number of hours) taken to initiate participants from enrollment (cardiac ICU admission) to initiation of assigned study mode of invasive mechanical ventilation upto 48 hours after enrollment.

    Time frame: Enrollment to 48 Hours

Secondary outcomes

  1. In-hospital Mortality (Exploratory Clinical Outcome)

    All-cause, 28-day, in-hospital mortality, defined as death from any cause occurring between enrollment and 28 days after enrollment.

    Time frame: Enrollment to Study Day 28

  2. Ventilator-Free Days (Exploratory Clinical Outcome)

    The number of calendar days between enrollment and 28 days after enrollment, on which the patient is alive and free of invasive mechanical ventilation.

    Time frame: Enrollment to Study Day 28

  3. Organ Failure Free Survival Days (Exploratory Clinical Outcome)

    The number of calendar days between enrollment and 28 days after enrollment, on which the patient is alive and free of invasive mechanical ventilation, renal replacement therapy, mechanical circulatory and vasoactive medication support.

    Time frame: Enrollment to Study Day 28

  4. Vasoactive-inotrope score (Exploratory Hemodynamic Outcome)

    The Vasoactive-Inotropic Score (VIS) is a quantitative measure of the total cardiovascular support a patient receives through vasopressors and inotropes, by a standardized conversion to per-kilogram per-minute units. Higher VIS indicates greater dependence on pharmacologic support and is associated with worse outcomes.

    Time frame: Enrollment to 48 hours

  5. Intensive Care Unit Length of Stay (Exploratory Clinical Outcome)

    Number of days between enrollment and 28 days after enrollment, on which the patient is alive and free from intensive care unit admission after the final transfer out of the intensive care unit

    Time frame: Enrollment to Study Day 28

  6. Patient Ventilator Dyssynchrony Events

    Number of participants with flow, trigger or cycle dyssynchrony during assigned study mode for invasive mechanical ventilation.

    Time frame: Enrollment to 48 hours

  7. Exhaled Tidal Volume (mL/kg Predicted Body Weight) (Exploratory Ventilatory Outcome)

    Measured in mL/kg of predicted body weight

    Time frame: Enrollment to 48 hours

  8. Median RASS Score (Exploratory Safety Outcome)

    RASS is a 10-point scale of agitation or sedation ranging from -5 (most sedated, comatose) to +4 (most agitated, combative). The sedation requirement for each ventilator mode will be assessed via RASS score.

    Time frame: Enrollment to 48 hours

07

Study locations

1 of 1 sites recruiting
  • Mayo Clinic, 1216 Second Street SW
    Rochester, Minnesota 55905, United States
    Recruiting
08

References and documents

Publications

  • Seitz KP, Lloyd BD, Wang L, Shotwell MS, Qian ET, Muhs AL, Richardson RK, Rooks JC, Hennings-Williams V, Sandoval CE, Richardson WD, Morgan TL, Thompson AN, Hastings PG, Ring TP, Stollings JL, Talbot EM, Krasinski DJ, DeCoursey BR, Marvi TK, DeMasi SC, Gibbs KW, Self WH, Mixon AS, Rice TW, Semler MW; Pragmatic Critical Care Research Group. Effect of Ventilator Mode on Ventilator-Free Days in Critically Ill Adults: A Randomized Trial. medRxiv [Preprint]. 2024 Oct 9:2024.10.08.24314961. doi: 10.1101/2024.10.08.24314961. PubMed 39417127 ↗
  • Zhou Y, Holets SR, Li M, Cortes-Puentes GA, Meyer TJ, Hanson AC, Schulte PJ, Oeckler RA. Etiology, incidence, and outcomes of patient-ventilator asynchrony in critically-ill patients undergoing invasive mechanical ventilation. Sci Rep. 2021 Jun 11;11(1):12390. doi: 10.1038/s41598-021-90013-z. PubMed 34117278 ↗
  • Al Shehri AM, El-Tahan MR, Al Metwally R, Qutub H, El Ghoneimy YF, Regal MA, Zien H. Right ventricular function during one-lung ventilation: effects of pressure-controlled and volume-controlled ventilation. J Cardiothorac Vasc Anesth. 2014 Aug;28(4):880-4. doi: 10.1053/j.jvca.2013.09.012. Epub 2014 Jan 18. PubMed 24447503 ↗
  • Kim KN, Kim DW, Jeong MA, Sin YH, Lee SK. Comparison of pressure-controlled ventilation with volume-controlled ventilation during one-lung ventilation: a systematic review and meta-analysis. BMC Anesthesiol. 2016 Aug 31;16(1):72. doi: 10.1186/s12871-016-0238-6. PubMed 27581657 ↗
  • Li XF, Mao WJ, Jiang RJ, Yu H, Zhang MQ, Yu H. Effect of Mechanical Ventilation Mode Type on Postoperative Pulmonary Complications After Cardiac Surgery: A Randomized Controlled Trial. J Cardiothorac Vasc Anesth. 2024 Feb;38(2):437-444. doi: 10.1053/j.jvca.2023.11.024. Epub 2023 Nov 19. PubMed 38105126 ↗
  • Rittayamai N, Katsios CM, Beloncle F, Friedrich JO, Mancebo J, Brochard L. Pressure-Controlled vs Volume-Controlled Ventilation in Acute Respiratory Failure: A Physiology-Based Narrative and Systematic Review. Chest. 2015 Aug;148(2):340-355. doi: 10.1378/chest.14-3169. PubMed 25927671 ↗
  • Alviar CL, Miller PE, McAreavey D, Katz JN, Lee B, Moriyama B, Soble J, van Diepen S, Solomon MA, Morrow DA; ACC Critical Care Cardiology Working Group. Positive Pressure Ventilation in the Cardiac Intensive Care Unit. J Am Coll Cardiol. 2018 Sep 25;72(13):1532-1553. doi: 10.1016/j.jacc.2018.06.074. PubMed 30236315 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Feb 2027, 7 months after the start.

Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 7 months is below that.

Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 18, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Jun 30, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07656259
Lead sponsor
Mayo Clinic
Responsible party
Garima Dahiya (Assistant Professor of Medicine, Mayo Clinic) — Principal investigator
First posted
Jun 18, 2026
Start date
Jul 1, 2026
Primary completion
Feb 28, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion